iDiagnostics is the future of precision medicine. With your help we will make iDiagnostics available for all. Additionally, iDiagnostics will help to minimize the risk of humanity self-eradication. iDiagnostics employs TIRF microarray technology; to learn more about TIRF visit www.tirf-labs.com
Handheld Molecular iDiagnostics
by TIRF Labs
Future applications for iDiagnostics will include tests for the diagnosis and prognosis of cancer, cardio-vascular diseases, Alzheimer's disease (and other neurological disorders), longevity studies, diagnosing of influenza, Ebola, HIV/AIDS, Zika, STDs (and other infectious diseases), food and water safety, biodefense, and forensic, environmental, military, and agricultural analyses. We believe that many routine analyses of blood, urine and other bodily fluids that currently are performed in clinical labs, will migrate to iDiagnostics, because of the convenience of home use tests. Along with the main goal of home use, family doctors, cardiologists, dentists, first responders, pharmaceutical companies, food safety, agriculture, and environment protection specialists have expressed their interest in using iDiagnostics for their applications. There are thousands of new applications that can be developed for the iDiagnostics platform. It is too difficult, if not impossible, for a single company to develop all of these numerous applications. Therefore, we invite other research groups worldwide to join our virtual team to interface their existing tests and develop new applications with the iDiagnostics platform.
To facilitate these efforts, we are offering the uTIRF Biodetection Station and iDiagnostics Application Development Kit (ADK), as mentioned above. We anticipate a large demand for uTIRF-ADK, because there are tens of thousands of research groups worldwide that develop diagnostic assays, discover and validate molecular markers, and investigate the molecular mechanisms of related biological processes. These research applications do not need FDA approvals. However, they will naturally pave the road for medical use of iDiagnostics.
In our laboratory in North Carolina, we are developing diagnostic and prognostic tests for prostate cancer. We have developed iDiagnostics tests for food safety and detecting allergens in food. Our long-term collaborator Dr. Vaca from the Institute of Cellular Physiology at UNAM and his group are developing preemptive diagnostic tests for Alzheimer's disease and hepatitis C. His colleagues from other research groups will develop tests for pancreatic and colon cancer. Dr. Dong from Washington State University is developing tests for cardiovascular diseases. The Laboratory of Molecular Virology at the Food and Drug Administration have expressed their interest in using iDiagnostics for the rapid detection of HIV and other infectious diseases.
There are hundreds of other exciting applications that will be completely new for the healthcare area. In our laboratory in North Carolina we are also working on longevity tests. These studies promise rapid progress in lengthening the average life span, and preventing metabolic disbalances that result in premature aging. Personalized precision medicine of the future, clinical and pre-clinical tests of new drugs, disease risks assessment, food and water safety, detection of allergens, and environmental and agricultural applications will benefit tremendously from iDiagnostics.